Pyridazinedione-based heterobicyclic covalent linkers and methods and applications thereof
US-2024425465-A1 · Dec 26, 2024 · US
Pyrimido-diazepinone compounds and methods of treating disorders
US9676792B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9676792-B2 |
| Application number | US-201414775897-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 17, 2014 |
| Priority date | Mar 15, 2013 |
| Publication date | Jun 13, 2017 |
| Grant date | Jun 13, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3, Aurora, Axl, Bmx, BTK, c-kit, CHK2, Flt3, MST2, p70S6K, PDGFR, PKB, PKC, Raf, ROCK-H, Rsk1, SGK, TrkA, TrkB and TrkC, and the use of such compounds in the treatment of various diseases, disorders or conditions.
First claim
Opening claim text (preview).
What is claimed: 1. A compound of formula V: or a pharmaceutically acceptable salt thereof, wherein, X is hydrogen; R 2 is hydrogen or alkyl; R 3 is —OH or O-(alkyl); R 4 is hydrogen or alkyl; R 6 is hydrogen or alkyl; and R′ is hydrogen. 2. The compound of claim 1 , wherein R 2 is H, methyl, or ethyl. 3. The compound of claim 1 , wherein R 6 is H. 4. The compound of claim 1 , wherein R 3 is —OCH 3 or —OCH 2 CH 3 . 5. The compound of claim 1 , wherein R 4 is methyl or ethyl. 6. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier.
Assignees
Inventors
Classifications
Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Drugs for disorders of the cardiovascular system · CPC title
specific for metastasis · CPC title
Drugs for disorders of the blood or the extracellular fluid · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9676792B2 cover?
- The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including MPS1 (TTK), ERK5 (BMK1, MAPK7), LRKK2, EphA2, polo kinase 1, 2, 3, or 4, Ack1, Ack2, Abl, DCAMKL1, ABL1, Abl mutants, DCAMKL2, ARK5, BRK, MKNK2, FGFR4, TNK1, PLK1, ULK2, PLK4, PRKD1, PRKD2, PRKD3, ROS1, RPS6KA6, TAOK1, TAOK3, TNK2, Bcr-Abl, GAK, cSrc, TPR-Met, Tie2, MET, FGFR3…
- Who is the assignee on this patent?
- Dana Farber Cancer Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification C07D513/04. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Jun 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).